chronic inflammatory conditions
LEO Pharma elects Henriette Mersebach to the Board of Directors
Mersebach previously held senior leadership positions at ALK-Abelló and Novo Nordisk
LEO Pharma acquires rights for dersimelagon from Tanabe Pharma
The company will pay $435m in up front and near-term milestone payments
LEO Pharma and Allergy UK launch ‘Don’t Ignore’ chronic hand eczema campaign
The campaign aims to improve awareness and understanding of the condition
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Matt Ferriday announced as General Manager for LEO Pharma UK
Ferriday most recently held senior leadership roles at Ipsen Biopharma
LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus
There are currently no approved treatments specifically indicated for LS in the US or Europe
LEO Pharma receives NICE approval for chronic hand eczema cream
The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable
LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema
The cream is now the first treatment approved by the regulator specifically for this patient population
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
LEO Pharma and the Parker Institute join forces to advance dermatology research
The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
Approximately 125 million people worldwide are affected by some form of the inflammatory condition
LEO and DEBRA Research partner to advance epidermolysis bullosa treatments
There is currently no cure for the group of rare inherited skin disorders